^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
EDP1503
i
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
Evelo Biosci
Drug class:
Microbiome modulator
Related drugs:
Phase 2
University of Chicago
Active, not recruiting
Last update posted :
07/31/2024
Initiation :
10/02/2018
Primary completion :
11/02/2027
Completion :
11/02/2027
BRAF
|
Keytruda (pembrolizumab) • EDP1503
Share
